EGFR and non-small cell lung carcinoma: Based on the findings from our retrospective study, we also conducted preliminary in vitro assays to evaluate the efficacy of anlotinib and in combination with osimertinib in EGFR T790M‐mutant osimertinib‐resistant NSCLC cell line H1975OR.